


10. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. The use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of ~~A method of treating~~ a disease or disorder associated with the inhibition of the PD-1/PD-L1 interaction, the method comprising administering to a mammalian patient ~~a~~ said medicament~~compound according to claim 1 or a pharmaceutically acceptable salt~~.

12. The ~~method~~ use according to claim 11 wherein said disease or disorder is a virological infection or cancer.